Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| ABCA4 | ATP-binding cassette subfamily A member 4 |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| AUCinf | Area under the concentration-time curve extrapolated to infinity |
| BCVA | Best-corrected visual acuity |
| BD | Twice daily |
| CI | Confidence interval |
| Cmax | Maximum plasma concentration |
| CYP3A | Cytochrome P450 3A |
| DAF | Decreased autofluorescence |
| DDAF | Definitely decreased autofluorescence |
| DNA | Deoxyribonucleic acid |
| FAF | Fundus autofluorescence |
| FDA | Food and Drug Administration |
| GLS | Geometric least squares |
| IQR | Interquartile range |
| IRD | Inherited retinal disease |
| IVI | Impact of Vision Impairment |
| logMAR | Logarithm of the minimum angle of resolution |
| mFAS | Modified full analysis set |
| mMP | Mesopic microperimetry |
| MMRM | Mixed Model for Repeated Measures |
| NDA | New Drug Application |
| NEI VFQ | National Eye Institute Visual Function Questionnaire |
| p.o. | Orally |
| qAF | Quantitative autofluorescence |
| QD | Once daily |
| QDAF | Questionably decreased autofluorescence |
| QoL | Quality of life |
| RBP4 | Retinol-binding protein 4 |
| REC | Research Ethics Committee |
| SD | Stargardt disease |
| STGD | Stargardt disease |
| STGD1 | Stargardt disease type 1 |
| TEAE | Treatment-emergent adverse event |
| USD | United States dollar |